Richard Boland, MD, AGAF, Michael Camilleri, MD, AGAF, Kiron M. Das, MD, PhD, AGAF, Ralph A. Giannella, MD, AGAF, Gail A. Hecht, MD, MS, AGAF, Lawrence S. Kim, MD, AGAF, Loren Laine, MD, AGAF, Nicholas F. LaRusso, MD, AGAF, David A. Peura, MD, AGAF Distinguished Chair: John I. Allen, MD, AGAF, James W. Freston, MD, PhD, AGAF, Barry J. Marshall, MD, AGAF, Daniel K. Podolsky, MD, AGAF, Marvin H. Sleisenger, MD, AGAF, Tadataka Yamada, MD, AGAF In addition, AGA would like to recognize the Looking Forward: Giving Back campaign's many generous donors. Their gifts will make an instantaneous difference in the careers of young researchers and in the lives of countless patients who will reap the benefits of their function. John I. Allen, MD, MBA, AGAF & Carolyn Allen Anonymous Sumner and Susan Bell Athena Blackburn Boston Scientific Braintree Laboratories, Inc.Inside our cohort, transplant recipients with HLA-C2/C2 indeed had an elevated risk of relapse, in comparison with recipients with HLA-C1/C1 or HLA-C1/C2 . In recipients with HLA-C2/C2, allografts from KIR2DS1-positive donors did not provide security from relapse . On the other hand, patients with HLA-C1/C1 or C1/C2 benefited significantly from receiving an allograft from a KIR2DS1-positive donor . The increased prices of relapse connected with allografts from donors with HLA-C2/C2, both KIR2DS1-positive and KIR2DS1-negative , nevertheless, indicate that furthermore to tolerizing KIR2DS1-bearing NK cells in the donor, HLA-C2/C2 homozygosity is certainly associated with an increased rate of relapse due to causes that are unrelated to KIR2DS1.